JP2011500847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500847A5 JP2011500847A5 JP2010531290A JP2010531290A JP2011500847A5 JP 2011500847 A5 JP2011500847 A5 JP 2011500847A5 JP 2010531290 A JP2010531290 A JP 2010531290A JP 2010531290 A JP2010531290 A JP 2010531290A JP 2011500847 A5 JP2011500847 A5 JP 2011500847A5
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- ppm
- specifically
- inflammation
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 47
- 239000012530 fluid Substances 0.000 claims description 46
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 13
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 10
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 10
- 210000000170 cell membrane Anatomy 0.000 claims description 10
- 201000004624 Dermatitis Diseases 0.000 claims description 9
- 230000004068 intracellular signaling Effects 0.000 claims description 9
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 claims description 8
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 8
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 8
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 8
- 206010040070 Septic Shock Diseases 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 210000004379 membrane Anatomy 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 201000004700 rosacea Diseases 0.000 claims description 7
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 6
- 102000034353 G alpha subunit Human genes 0.000 claims description 6
- 108091006099 G alpha subunit Proteins 0.000 claims description 6
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims description 6
- 206010020565 Hyperaemia Diseases 0.000 claims description 6
- 241001303601 Rosacea Species 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 229960004436 budesonide Drugs 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 4
- 206010013774 Dry eye Diseases 0.000 claims description 4
- 206010014824 Endotoxic shock Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 4
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 4
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 4
- 208000000491 Tendinopathy Diseases 0.000 claims description 4
- 206010043255 Tendonitis Diseases 0.000 claims description 4
- 241000159243 Toxicodendron radicans Species 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 206010052428 Wound Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 108060000200 adenylate cyclase Proteins 0.000 claims description 4
- 102000030621 adenylate cyclase Human genes 0.000 claims description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 4
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 4
- 208000010217 blepharitis Diseases 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 239000000812 cholinergic antagonist Substances 0.000 claims description 4
- 208000007451 chronic bronchitis Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 230000006020 chronic inflammation Effects 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 210000000744 eyelid Anatomy 0.000 claims description 4
- 229960002714 fluticasone Drugs 0.000 claims description 4
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 4
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 4
- 229960002848 formoterol Drugs 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 229960001888 ipratropium Drugs 0.000 claims description 4
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 4
- 208000001875 irritant dermatitis Diseases 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 150000002617 leukotrienes Chemical class 0.000 claims description 4
- 201000003265 lymphadenitis Diseases 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000005962 mycosis fungoides Diseases 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 229960002052 salbutamol Drugs 0.000 claims description 4
- 229960004017 salmeterol Drugs 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- 230000036303 septic shock Effects 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 201000004415 tendinitis Diseases 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- 102000027257 transmembrane receptors Human genes 0.000 claims description 4
- 108091008578 transmembrane receptors Proteins 0.000 claims description 4
- 239000002435 venom Substances 0.000 claims description 4
- 231100000611 venom Toxicity 0.000 claims description 4
- 210000001048 venom Anatomy 0.000 claims description 4
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 206010015943 Eye inflammation Diseases 0.000 claims description 3
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000003401 eosinophilic granuloma Diseases 0.000 claims description 3
- 210000003630 histaminocyte Anatomy 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 2
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 208000003367 Hypopigmentation Diseases 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102000004890 Interleukin-8 Human genes 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims description 2
- 208000006311 Pyoderma Diseases 0.000 claims description 2
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 102000014384 Type C Phospholipases Human genes 0.000 claims description 2
- 108010079194 Type C Phospholipases Proteins 0.000 claims description 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229960001692 arformoterol Drugs 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229940092705 beclomethasone Drugs 0.000 claims description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
- 208000002352 blister Diseases 0.000 claims description 2
- 230000036760 body temperature Effects 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 230000021164 cell adhesion Effects 0.000 claims description 2
- 229960001803 cetirizine Drugs 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 claims description 2
- 210000000795 conjunctiva Anatomy 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 229960000265 cromoglicic acid Drugs 0.000 claims description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 210000001047 desmosome Anatomy 0.000 claims description 2
- 229910001882 dioxygen Inorganic materials 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 229960000676 flunisolide Drugs 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 210000003976 gap junction Anatomy 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960000930 hydroxyzine Drugs 0.000 claims description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 2
- 208000000069 hyperpigmentation Diseases 0.000 claims description 2
- 230000003810 hyperpigmentation Effects 0.000 claims description 2
- 230000003425 hypopigmentation Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 230000031146 intracellular signal transduction Effects 0.000 claims description 2
- 230000007803 itching Effects 0.000 claims description 2
- 229950008204 levosalbutamol Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 229960001664 mometasone Drugs 0.000 claims description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 2
- 229960005127 montelukast Drugs 0.000 claims description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- 229960004398 nedocromil Drugs 0.000 claims description 2
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 201000005111 ocular hyperemia Diseases 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 229960005330 pimecrolimus Drugs 0.000 claims description 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 2
- 229960005414 pirbuterol Drugs 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 229960000278 theophylline Drugs 0.000 claims description 2
- 210000001578 tight junction Anatomy 0.000 claims description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 2
- 229940110309 tiotropium Drugs 0.000 claims description 2
- 229960005294 triamcinolone Drugs 0.000 claims description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004764 zafirlukast Drugs 0.000 claims description 2
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims description 2
- 229960005332 zileuton Drugs 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010072139 Ocular rosacea Diseases 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000009134 cell regulation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 210000004692 intercellular junction Anatomy 0.000 claims 1
- 235000013372 meat Nutrition 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98272007P | 2007-10-25 | 2007-10-25 | |
| US98271907P | 2007-10-25 | 2007-10-25 | |
| US60/982,719 | 2007-10-25 | ||
| USPCT/US2007/082581 | 2007-10-25 | ||
| USPCT/US2007/082580 | 2007-10-25 | ||
| PCT/US2007/082578 WO2008052143A2 (en) | 2006-10-25 | 2007-10-25 | Mixing device and output fluids of same |
| US60/982,720 | 2007-10-25 | ||
| PCT/US2007/082580 WO2008052145A2 (en) | 2006-10-25 | 2007-10-25 | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| PCT/US2007/082581 WO2008115290A2 (en) | 2006-10-25 | 2007-10-25 | Methods of wound care and treatment |
| USPCT/US2007/082578 | 2007-10-25 | ||
| US4834008P | 2008-04-28 | 2008-04-28 | |
| US4840408P | 2008-04-28 | 2008-04-28 | |
| US4833208P | 2008-04-28 | 2008-04-28 | |
| US4834708P | 2008-04-28 | 2008-04-28 | |
| US61/048,404 | 2008-04-28 | ||
| US61/048,340 | 2008-04-28 | ||
| US61/048,347 | 2008-04-28 | ||
| US61/048,332 | 2008-04-28 | ||
| PCT/US2008/081202 WO2009055729A1 (en) | 2007-10-25 | 2008-10-24 | Compositions and methods for treating inflammation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014121350A Division JP2014169328A (ja) | 2007-10-25 | 2014-06-12 | 炎症を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500847A JP2011500847A (ja) | 2011-01-06 |
| JP2011500847A5 true JP2011500847A5 (https=) | 2012-12-06 |
| JP5869763B2 JP5869763B2 (ja) | 2016-02-24 |
Family
ID=42261767
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531255A Expired - Fee Related JP5613565B2 (ja) | 2007-10-25 | 2008-10-23 | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
| JP2010531276A Expired - Fee Related JP5911197B2 (ja) | 2007-10-25 | 2008-10-24 | 嚢胞性線維症を治療するための組成物および方法 |
| JP2010531290A Active JP5869763B2 (ja) | 2007-10-25 | 2008-10-24 | 炎症を治療するための組成物および方法 |
| JP2014117564A Pending JP2014193915A (ja) | 2007-10-25 | 2014-06-06 | 嚢胞性線維症を治療するための組成物および方法 |
| JP2014121357A Withdrawn JP2014205693A (ja) | 2007-10-25 | 2014-06-12 | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
| JP2014121350A Withdrawn JP2014169328A (ja) | 2007-10-25 | 2014-06-12 | 炎症を治療するための組成物および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531255A Expired - Fee Related JP5613565B2 (ja) | 2007-10-25 | 2008-10-23 | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
| JP2010531276A Expired - Fee Related JP5911197B2 (ja) | 2007-10-25 | 2008-10-24 | 嚢胞性線維症を治療するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014117564A Pending JP2014193915A (ja) | 2007-10-25 | 2014-06-06 | 嚢胞性線維症を治療するための組成物および方法 |
| JP2014121357A Withdrawn JP2014205693A (ja) | 2007-10-25 | 2014-06-12 | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
| JP2014121350A Withdrawn JP2014169328A (ja) | 2007-10-25 | 2014-06-12 | 炎症を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP2215260A4 (https=) |
| JP (6) | JP5613565B2 (https=) |
| CN (5) | CN101910412B (https=) |
| AU (3) | AU2008316794B2 (https=) |
| CA (3) | CA2703672A1 (https=) |
| IL (3) | IL205319A (https=) |
| MX (3) | MX2010004563A (https=) |
| WO (1) | WO2009055614A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
| US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| AU2007308838B2 (en) | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| MX2010004549A (es) * | 2007-10-25 | 2010-07-28 | Revalesio Corp | Composiciones y métodos bacteriostáticos o bactericidas. |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| AU2009241365B2 (en) * | 2008-04-28 | 2015-01-22 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US8980325B2 (en) | 2008-05-01 | 2015-03-17 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| CA2741336A1 (en) * | 2008-10-22 | 2010-04-29 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| AU2010241736B2 (en) * | 2009-04-27 | 2016-01-28 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| BR112012028540A2 (pt) * | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
| KR20130050952A (ko) | 2010-06-16 | 2013-05-16 | 브루스 챈들러 메이 | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 |
| JP2013533320A (ja) | 2010-08-12 | 2013-08-22 | レバレジオ コーポレイション | タウオパチーを治療するための組成物および方法 |
| KR20130100126A (ko) * | 2010-08-13 | 2013-09-09 | 레발레시오 코퍼레이션 | 심혈관 질환을 치료하기 위한 조성물 및 방법 |
| US20120263764A1 (en) * | 2011-04-13 | 2012-10-18 | Revalesio Corporation | Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease |
| JP6368459B2 (ja) * | 2012-06-14 | 2018-08-01 | 松本 高明 | 点眼液の製造方法 |
| RU2015134423A (ru) | 2013-03-13 | 2017-04-26 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств |
| MX382776B (es) | 2013-03-13 | 2025-03-13 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. |
| WO2014164285A2 (en) | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| WO2016044095A1 (en) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| CN106943593A (zh) * | 2017-03-24 | 2017-07-14 | 浙江中医药大学 | 抗tslp抗体在制备防治慢性瘙痒药物中的应用 |
| CA3064050A1 (en) * | 2017-05-23 | 2018-11-29 | Biovite Australia Pty Ltd. | Extracts from arthrospira and uses thereof |
| WO2021236518A1 (en) | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| CN112305153B (zh) * | 2020-10-16 | 2022-09-23 | 中石化石油工程技术服务有限公司 | 一种膨润土含量的自动分析检测仪及其检测方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518483D0 (en) * | 1995-09-09 | 1995-11-08 | Thompson Royce Ltd | Lighting control systems |
| US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
| US6386751B1 (en) * | 1997-10-24 | 2002-05-14 | Diffusion Dynamics, Inc. | Diffuser/emulsifier |
| EP1100811B1 (en) * | 1998-07-28 | 2007-07-04 | The Regents Of The University Of California | Nucleic acids encoding a g-protein coupled receptor involved in sensory transduction |
| EP1237578A4 (en) * | 1999-10-26 | 2004-10-27 | Bio Hydration Res Lab Inc | MICRO-AGGREGATED LIQUIDS AND METHODS OF MAKING AND USING SAME |
| US20060198901A9 (en) * | 1999-10-26 | 2006-09-07 | Holloway William D Jr | Drugs, bio-affecting and body treating compositions |
| WO2001042451A2 (en) * | 1999-12-08 | 2001-06-14 | Genset | FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS |
| US7255881B2 (en) * | 2000-07-27 | 2007-08-14 | Nucryst Pharmaceuticals Corp. | Metal-containing materials |
| WO2002024222A2 (en) * | 2000-09-20 | 2002-03-28 | The Cleveland Clinic Foundation | Ligands for g protein coupled receptors and methods of using them |
| US20040235732A1 (en) * | 2000-11-03 | 2004-11-25 | Qun-Yong Zhou | Method for modulating angiogenesis using prokineticin receptor antagonists |
| EP1357920B1 (en) * | 2001-02-01 | 2007-09-05 | Hydron Technologies Inc. | Compositions and method of tissue superoxygenation |
| GB0118383D0 (en) * | 2001-07-27 | 2001-09-19 | Pharmagene Lab Ltd | Therapeutic methods |
| DE10227818A1 (de) * | 2002-06-21 | 2004-01-08 | Pakdaman, Abolghassem, Prof. Dr.med. | Gasanreicherungsmodule |
| AU2002321678A1 (en) * | 2002-09-09 | 2004-03-29 | Boros Béla | Oxygen-enriched water, treated within a magnetic field and heavy water |
| US7790762B2 (en) * | 2002-10-31 | 2010-09-07 | National Jewish Health | Compounds and methods for thiol-containing compound efflux and cancer treatment |
| US7491695B2 (en) * | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| ATE500234T1 (de) * | 2003-11-10 | 2011-03-15 | Merck Sharp & Dohme | Substituierte trialzole als blocker des natriumkanals |
| US20050139808A1 (en) * | 2003-12-30 | 2005-06-30 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and process for producing same |
| US20060073212A1 (en) * | 2004-04-22 | 2006-04-06 | Palmer Craig R | Method of treating respiratory disorders and airway inflammation |
| AU2005329764B2 (en) * | 2005-03-28 | 2010-08-12 | Dabur Pharma Ltd. | Stable pharmaceutical compositions of platinum (II) antitumour agents |
| EP1901749B1 (en) * | 2005-05-18 | 2016-08-03 | Raptor Pharmaceuticals Inc. | Aerosolized fluoroquinolones and uses thereof |
| GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| US8597689B2 (en) * | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| AU2007308838B2 (en) * | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| JP5491185B2 (ja) * | 2006-10-25 | 2014-05-14 | リバルシオ コーポレイション | 傷のケアおよび処置の方法 |
| MX2010004549A (es) * | 2007-10-25 | 2010-07-28 | Revalesio Corp | Composiciones y métodos bacteriostáticos o bactericidas. |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
-
2008
- 2008-10-23 EP EP08842968A patent/EP2215260A4/en not_active Withdrawn
- 2008-10-23 JP JP2010531255A patent/JP5613565B2/ja not_active Expired - Fee Related
- 2008-10-23 WO PCT/US2008/081021 patent/WO2009055614A1/en not_active Ceased
- 2008-10-23 AU AU2008316794A patent/AU2008316794B2/en not_active Ceased
- 2008-10-23 MX MX2010004563A patent/MX2010004563A/es active IP Right Grant
- 2008-10-23 CA CA2703672A patent/CA2703672A1/en not_active Abandoned
- 2008-10-23 CN CN200880122893XA patent/CN101910412B/zh not_active Expired - Fee Related
- 2008-10-24 CN CN201510111837.8A patent/CN104771758A/zh active Pending
- 2008-10-24 JP JP2010531276A patent/JP5911197B2/ja not_active Expired - Fee Related
- 2008-10-24 EP EP08841991A patent/EP2224924A4/en not_active Withdrawn
- 2008-10-24 AU AU2008316623A patent/AU2008316623B2/en active Active
- 2008-10-24 CN CN201410108422.0A patent/CN103933567A/zh active Pending
- 2008-10-24 CA CA2703739A patent/CA2703739A1/en not_active Abandoned
- 2008-10-24 CA CA2703754A patent/CA2703754C/en active Active
- 2008-10-24 AU AU2008316663A patent/AU2008316663B2/en not_active Ceased
- 2008-10-24 CN CN200880122816.4A patent/CN101909623B/zh not_active Expired - Fee Related
- 2008-10-24 CN CN200880122817.9A patent/CN101909648B/zh active Active
- 2008-10-24 MX MX2010004564A patent/MX2010004564A/es active IP Right Grant
- 2008-10-24 MX MX2010004554A patent/MX2010004554A/es active IP Right Grant
- 2008-10-24 EP EP08841701.9A patent/EP2214707B1/en active Active
- 2008-10-24 JP JP2010531290A patent/JP5869763B2/ja active Active
-
2010
- 2010-04-25 IL IL205319A patent/IL205319A/en not_active IP Right Cessation
- 2010-04-25 IL IL205317A patent/IL205317A/en not_active IP Right Cessation
- 2010-04-25 IL IL205318A patent/IL205318A/en active IP Right Grant
-
2014
- 2014-06-06 JP JP2014117564A patent/JP2014193915A/ja active Pending
- 2014-06-12 JP JP2014121357A patent/JP2014205693A/ja not_active Withdrawn
- 2014-06-12 JP JP2014121350A patent/JP2014169328A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500847A5 (https=) | ||
| JP2012506451A5 (https=) | ||
| US9492404B2 (en) | Compositions and methods for treatment of taupathy | |
| CN101909648B (zh) | 用于治疗炎症的组合物和方法 | |
| JP2011523627A5 (https=) | ||
| Liu et al. | Cervical sympathetic block regulates early systemic inflammatory response in severe trauma patients | |
| JP2014511879A5 (https=) | ||
| JP5539965B2 (ja) | 多発性硬化症を治療するための組成物および方法 | |
| US20100015235A1 (en) | Compositions and methods for treating multiple sclerosis | |
| CN101909649A (zh) | 用于治疗哮喘和其他肺病患的组合物和方法 | |
| KR20230015518A (ko) | 신경활성 스테로이드, 그의 조성물, 및 용도 | |
| CA2994545A1 (en) | Charged ion channel blockers and methods for use | |
| BRPI0920201A2 (pt) | composicoes e metodos para tratar condicoes mediadas por linfopoetina do estroma timico(tslp) | |
| Xu et al. | Inhibiting high-mobility group box 1 (HMGB1) attenuates inflammatory cytokine expression and neurological deficit in ischemic brain injury following cardiac arrest in rats | |
| CA2798127A1 (en) | Methods and compositions for protecting against neurotoxic agents | |
| KR20140095549A (ko) | ４－프레게넨－１１β－１７－２１－트리올－３，２０－디온 유도체의 약학적 조성물 및 이의 사용 방법 | |
| Chen et al. | Paeoniflorin regulates the hypothalamic-pituitary-adrenal axis negative feedback in a rat model of post-traumatic stress disorder | |
| CN104546928B (zh) | 一种治疗小儿尿布疹的中药组合物及其制备方法 | |
| Ciprandi et al. | Comano thermal water inhalations in the treatment of allergic rhinitis: preliminary results | |
| US20170239198A1 (en) | Capsaicinoids and uses thereof as medicaments | |
| US10314835B2 (en) | Methods of managing conditioned fear with neurokinin receptor antagonists | |
| JP2022507794A (ja) | 電解水による皮膚疾患の処置 | |
| BR112020008350A2 (pt) | moduladores agonísticos de receptor de glicocorticóide seletivos (segrams) não esteroidais e usos dos mesmos | |
| Suzuki et al. | C-fiber-selective peripheral nerve blockade | |
| Yousefi et al. | Oxidative damage abolishes the ability of SP-D to block eosinophil extracellular DNA trap release during exacerbation of allergic airway inflammation |